描述焦点耐药性患者:一个回顾性队列研究
Caroline Benoist1, Simona Boccaletti1, John Paul Leach1
1Angelini Pharma S.p.A.; Viale Amelia 70, 00181 Rome, Italy.
Epilepsy & behavior : E&B
|November 25, 2023
概括
这项研究分析了六个欧洲国家的焦点耐药性 (F-DRE),揭示了抑郁症和焦虑症等常见的并发症. 治疗结果各不相同,强调个性化抗发作药物 (ASM) 选择.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 焦点抗药性 (F-DRE) 影响着欧洲各地的大量患者.
- 了解F-DRE的人口结构和治疗模式对于优化患者护理至关重要.
- 现有的数据可能无法完全捕捉不同欧洲医疗保健系统中F-DRE管理的细微差别.
研究的目的:
- 确定患有F-DRE的个体的人口和临床概况.
- 评估抗发作药物 (ASM) 治疗结果和F-DRE患者的医疗资源利用情况.
- 为了比较这些特征和结果在六个不同的欧洲国家.
主要方法:
- 利用来自比利时,西班牙,意大利,法国,英国和德国的初级和专科护理的电子病历数据.
- 确定的抗发作药物 (ASM) 在F-DRE诊断时18岁或以上的未经治疗的个体.
- 进行了描述性分析,报告结果按国家分层,并进行后续调查,直到研究结束或死亡.
主要成果:
- 包括1,070名F-DRE患者 (平均年龄52.5岁,55.4%为女性);中位数随访时间为95.5个月.
- 精神病并发症,特别是抑郁症 (26.7%) 和焦虑症 (11.8%),在所有国家中最常见.
- 到第一个ASM失败的中位时间因国家而异,从法国5.9个月到西班牙12.6个月; levetiracetam和lamotrigine是最常见的单一疗法.
结论:
- 没有一种单一的抗发作药物 (ASM) 对焦点耐药性 (F-DRE) 是普遍最佳的.
- 在选择ASM时,应仔细权衡个别风险和好处.
- 管理策略必须整合并发症的管理,以指导药物选择.
相关概念视频
01:24Arteries of the Lower Limbs
192
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
192
01:20Antiepileptic Drugs: Potassium Channel Activators
186
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
186
01:13Seizures: Classification
373
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
373
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
314
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
314